share_log

Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated at StockNews.com

Genocea Biosciences (NASDAQ:GNCA) Coverage Initiated at StockNews.com

Genocea Biosciences（纳斯达克股票代码：GNCA）的报道始于 StockNe
Financial News Live ·  2022/08/12 22:52

StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a research note published on Tuesday. The firm issued a sell rating on the biotechnology company's stock.

斯托克新闻网在周二发布的一份研究报告中开始报道基因生物科学公司(纳斯达克代码：GNCA-GET Rating)的股票。该公司对这家生物技术公司的股票发布了卖出评级。

A number of other equities analysts have also recently issued reports on GNCA. HC Wainwright cut Genocea Biosciences from a buy rating to a neutral rating in a report on Friday, April 29th. Stifel Nicolaus cut Genocea Biosciences from a buy rating to a hold rating in a report on Friday, April 29th. Finally, Robert W. Baird lowered their target price on Genocea Biosciences from $8.00 to $3.00 in a report on Monday, April 11th.

其他一些股票分析师最近也发布了关于GNCA的报告。在4月29日星期五的一份报告中，HC Wainwright将Genocea Biosciences的评级从买入下调至中性。Stifel Nicolaus在4月29日星期五的一份报告中将Genocea Biosciences的评级从买入下调至持有。最后，罗伯特·W·贝尔德在4月11日星期一的一份报告中将Genocea Biosciences的目标价从8.00美元下调至3.00美元。

Get
到达
Genocea Biosciences
Genocea生物科学
alerts:
警报：

Genocea Biosciences Stock Performance

Genocea Bioscions股票表现

GNCA opened at $0.01 on Tuesday. The business has a fifty day moving average of $0.02 and a 200 day moving average of $0.50. Genocea Biosciences has a 52-week low of $0.01 and a 52-week high of $2.20. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35.

GNCA周二开盘报0.01美元。该业务的50日移动均线切入位在0.02美元，200日移动均线切入位在0.50美元。Genocea Biosciences的52周低点为0.01美元，52周高位为2.20美元。该公司的负债权益比率为0.24，速动比率为1.35，流动比率为1.35。

Insider Transactions at Genocea Biosciences

Genocea Biosciences的内幕交易

In related news, Director Ali Behbahani sold 4,445,093 shares of the company's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total transaction of $355,607.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, Director Ali Behbahani sold 4,445,093 shares of the company's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total transaction of $355,607.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Paul Edward Walker sold 5,931,843 shares of the company's stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $0.07, for a total value of $415,229.01. Following the transaction, the insider now directly owns 4,445,093 shares in the company, valued at $311,156.51. The disclosure for this sale can be found here. In the last three months, insiders sold 10,537,612 shares of company stock valued at $781,461. Corporate insiders own 1.61% of the company's stock.
在相关新闻中，董事Ali贝赫巴哈尼在一笔日期为5月25日(星期三)的交易中出售了4445,093股该公司股票。该股以0.08美元的平均价格出售，总成交金额为355,607.44美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过以下链接访问该文件。在相关新闻中，董事Ali贝赫巴哈尼在一笔日期为5月25日(星期三)的交易中出售了4445,093股该公司股票。该股以0.08美元的平均价格出售，总成交金额为355,607.44美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过以下链接访问该文件。此外，大股东保罗·爱德华·沃克在5月24日星期二的交易中出售了5931,843股公司股票。这些股票的平均价格为0.07美元，总价值为415,229.01美元。交易完成后，这位内部人士现在直接拥有该公司4,445,093股，价值311,156.51美元。此次拍卖的披露信息可在此处找到。在过去的三个月里，内部人士出售了10,537,612股公司股票，价值781,461美元。企业内部人士持有该公司1.61%的股份。

Institutional Inflows and Outflows

机构资金流入和流出

A hedge fund recently raised its stake in Genocea Biosciences stock. Commonwealth Equity Services LLC grew its position in Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the period. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 59.25% of the company's stock.

一家对冲基金最近增持了Genocea Biosciences股票。根据英联邦股权服务公司提交给美国证券交易委员会的最新Form 13F文件，该公司在Genocea Biosciences，Inc.(纳斯达克代码：GNCA-GET评级)的持仓在第四季度增长了49.4%。该公司持有这家生物技术公司31,981股股票，在此期间又购买了10,576股。截至最近一个季度末，英联邦股权服务公司拥有Genocea Biosciences公司约0.06%的股份，价值3.7万美元。对冲基金和其他机构投资者持有该公司59.25%的股票。

About Genocea Biosciences

关于Genocea生物科学

(Get Rating)

(获取评级)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Genocea Biosciences，Inc.是一家生物制药公司，发现和开发新型癌症免疫疗法。该公司使用其专有的发现平台ATLAS，该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。

Featured Stories

专题报道

  • Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
  • Look at Honeywell for a Steady and Diversified Stock
  • Why Invest in High-Yield Dividend Stocks?
  • Find and Profitably Trade Stocks at 52-Week Lows
  • Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
  • Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
  • 免费获取StockNews.com关于基因组生物科学的研究报告(GNCA)
  • 霍尼韦尔看好稳定和多元化的股票
  • 为什么要投资高收益股利股票？
  • 找到并获利于52周低点的股票交易
  • 迪士尼(NYSE：DIS)的股票刚刚给了投资者一个巨大的信号
  • 清洁能源法案通过后，太阳能股大放异彩

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发